[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,261,786
  • Shares Outstanding, K 179,565
  • Annual Sales, $ 1,272 M
  • Annual Income, $ -245,030 K
  • EBIT $ -269 M
  • EBITDA $ -162 M
  • 60-Month Beta 3.46
  • Price/Sales 6.63
  • Price/Cash Flow N/A
  • Price/Book 20.23

Options Overview Details

View History
  • Implied Volatility 81.76% (+1.08%)
  • Historical Volatility 73.68%
  • IV Percentile 88%
  • IV Rank 61.25%
  • IV High 95.11% on 10/10/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 6) 1.70 (3.98%)
  • Put/Call Vol Ratio 0.75
  • Today's Volume 23,709
  • Volume Avg (30-Day) 25,453
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 323,827
  • Open Int (30-Day) 341,459
  • Expected Range 40.99 to 44.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 4
  • High Estimate $-0.31
  • Low Estimate $-0.50
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) -13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.66 +0.07%
on 07/24/26
63.11 -32.36%
on 07/01/26
-9.25 (-17.81%)
since 06/24/26
3-Month
42.62 +0.16%
on 05/19/26
63.11 -32.36%
on 07/01/26
-9.43 (-18.09%)
since 04/24/26
52-Week
41.73 +2.30%
on 03/30/26
104.32 -59.08%
on 10/09/25
-20.65 (-32.60%)
since 07/24/25

Most Recent Stories

More News
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing...

TEM : 42.69 (-7.22%)
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Personalis ,...

PSNL : 11.78 (-3.60%)
TEM : 42.69 (-7.22%)
Tempus AI to Acquire Personalis in $1.5 Billion Deal to Expand Precision Oncology Platform

Tempus AI ($TEM) has agreed to acquire Personalis ($PSNL) in an all-stock transaction valued at approximately $1.5 billion in enterprise value, expanding its capabilities in minimal residual disease (MRD)...

PSNL : 11.78 (-3.60%)
TEM : 42.69 (-7.22%)
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth ...

PSNL : 11.78 (-3.60%)
TEM : 42.69 (-7.22%)
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth ...

PSNL : 11.78 (-3.60%)
TEM : 42.69 (-7.22%)
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

Findings from the multi-center Articulate Pro study show Paige Prostate improves diagnostic consistency, accelerates turnaround times, and reduces laboratory workloads

TEM : 42.69 (-7.22%)
Tempus to Report Second Quarter 2026 Financial Results on July 30

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026,...

TEM : 42.69 (-7.22%)
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 37.81 (-2.60%)
AZN : 169.26 (+0.59%)
MRK : 131.07 (+0.45%)
GILD : 129.31 (-1.18%)
TEM : 42.69 (-7.22%)
GSK : 51.35 (+1.20%)
ARKK : 71.89 (-2.63%)
BMY : 62.09 (+0.94%)
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc....

TEM : 42.69 (-7.22%)
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software ...

TEM : 42.69 (-7.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 49.00
2nd Resistance Point 47.72
1st Resistance Point 45.21
Last Price 42.69
1st Support Level 41.42
2nd Support Level 40.14
3rd Support Level 37.63

See More

52-Week High 104.32
Fibonacci 61.8% 80.41
Fibonacci 50% 73.03
Fibonacci 38.2% 65.64
Last Price 42.69
52-Week Low 41.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.